Temozolomide for treatment of brain metastases: A review of 21 clinical trials

World Journal of Clinical Oncology

Volumn 5, Issue 1, 2014, Pages 19-27

  Zhu, Wei ^a   Zhou, Li ^a   Qian, Jia Qi ^a   Qiu, Tian Zhu ^a   Shu, Yong Qian ^a   Liu, Ping ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Brain metastases; Clinical outcomes; Clinical trials; Solid tumours; Temozolomide

Indexed keywords

EID: 84938740826     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i1.19     Document Type: Review

References (42)

1. Ellis R, Gregor A. The treatment of brain metastases from lung cancer. Lung Cancer 1998; 20: 81-84 [PMID: 9711525 DOI: 10.1016/S0169-5002(98)00009-9]
2. Kelly K, Bunn PA. Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer 1998; 20: 85-91 [PMID: 9711526 DOI: 10.1016/S0169-5002(98)00020-8]
3. Lentzsch S, Reichardt P, Weber F, Budach V, Dörken B. Brain metastases in breast cancer: prognostic factors and management. Eur J Cancer 1999; 35: 580-585 [PMID: 10492631 DOI: 10.1016/S0959-8049(98)00421-3]
4. Wroński M, Arbit E, McCormick B. Surgical treatment of 70 patients with brain metastases from breast carcinoma. Cancer 1997; 80: 1746-1754 [PMID: 9351543 DOI: 10.1002/(SICI)1097-0142(19971101)80:9<1746::AID-CNCR8>3.0.CO;2-C]
5. Shaw HM, Balch CM, Soong SJ, Milton GW, McCarthy WH. Prognostic histopathological factors in malignant melanoma. Pathology 1985; 17: 271-274 [PMID: 4047730 DOI: 10.3109/003 13028509063766]
6. Hasegawa T, Kondziolka D, Flickinger JC, Germanwala A, Lunsford LD. Brain metastases treated with radiosurgery alone: an alternative to whole brain radiotherapy? Neurosurgery 2003; 52: 1318-1326; discussion 1326 [PMID: 12762877 DOI: 10.1227/01.NEU.0000064569.18914.DE]
7. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999; 45: 427-434 [PMID: 10487566 DOI: 10.1016/S0360-3016(99)00198-4]
8. Lee SM, Betticher DC, Thatcher N. Melanoma: chemotherapy. Br Med Bull 1995; 51: 609-630 [PMID: 7552084]
9. Quantin X, Khial F, Reme-Saumon M, Michel FB, Pujol JL. Concomitant brain radiotherapy and vinorelbine-ifosfamidecisplatin chemotherapy in brain metastases of non-small cell lung cancer. Lung Cancer 1999; 26: 35-39 [PMID: 10574679 DOI: 10.1016/S0169-5002(99)00071-9]
10. Postmus PE, Smit EF. Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol 1999; 10: 753-759 [PMID: 10470420 DOI: 10.1023/A:1008318515795]
11. van Vulpen M, Kal HB, Taphoorn MJ, El-Sharouni SY. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep 2002; 9: 683-688 [PMID: 12066192]
12. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl- 3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & amp; B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47: 5846-5852 [PMID: 3664486]
13. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler DL, Rowinsky EK. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003; 88: 1004-1011 [PMID: 12671695 DOI: 10.1038/sj.bjc.6600827]
14. Baker SD, Wirth M, Statkevich P, Reidenberg P, Alton K, Sartorius SE, Dugan M, Cutler D, Batra V, Grochow LB, Donehower RC, Rowinsky EK. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999; 5: 309-317 [PMID: 10037179]
15. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, Atkins M, Buzaid A, Skarlos D, Rankin EM. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004; 22: 2101-2107 [PMID: 15169796 DOI: 10.1200/JCO.2004.11.044]
16. Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, Malkin MG. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001; 53: 259-265 [PMID: 11718258 DOI: 10.1023/A:1012226718323]
17. Christodoulou C, Bafaloukos D, Linardou H, Aravantinos G, Bamias A, Carina M, Klouvas G, Skarlos D. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 2005; 71: 61-65 [PMID: 15719277 DOI: 10.1007/s11060-004-9176-0]
18. Dziadziuszko R, Ardizzoni A, Postmus PE, Smit EF, Price A, Debruyne C, Legrand C, Giaccone G. Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 2003; 39: 1271-1276 [PMID: 12763216 DOI: 10.1016/S0959-8049(03)00234-X]
19. Giorgio CG, Giuffrida D, Pappalardo A, Russo A, Santini D, Salice P, Blanco G, Castorina S, Failla G, Bordonaro R. Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung Cancer 2005; 50: 247-254 [PMID: 16039010 DOI: 10.1016/j.lungcan.2005.05.026]
20. Siena S, Crinò L, Danova M, Del Prete S, Cascinu S, Salvagni S, Schiavetto I, Vitali M, Bajetta E. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol 2010; 21: 655-661 [PMID: 19767314 DOI: 10.1093/annonc/mdp343]
21. Schadendorf D, Hauschild A, Ugurel S, Thoelke A, Egberts F, Kreissig M, Linse R, Trefzer U, Vogt T, Tilgen W, Mohr P, Garbe C. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann Oncol 2006; 17: 1592-1597 [PMID: 17005632 DOI: 10.1093/annonc/mdl148]
22. Addeo R, De Rosa C, Faiola V, Leo L, Cennamo G, Montella L, Guarrasi R, Vincenzi B, Caraglia M, Del Prete S. Phase 2 trial of temozolomide using protracted low-dose and wholebrain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer 2008; 113: 2524-2531 [PMID: 18798231 DOI: 10.1002/cncr.23859]
23. Mikkelsen T, Anderson J, Doyle TJ, Croteau D, Avedissian R, Ryu S, Schultz L. Phase I/II dose escalation trial of concurrent temozolomide and whole brain radiation therapy for multiple brain metastasis. J Neurooncol 2010; 100: 241-247 [PMID: 20431907 DOI: 10.1007/s11060-010-0187-8]
24. Kouvaris JR, Miliadou A, Kouloulias VE, Kolokouris D, Balafouta MJ, Papacharalampous XN, Vlahos LJ. Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. Onkologie 2007; 30: 361-366 [PMID: 17596744]
25. Hofmann M, Kiecker F, Wurm R, Schlenger L, Budach V, Sterry W, Trefzer U. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol 2006; 76: 59-64 [PMID: 16132502 DOI: 10.1007/s11060-005-2914-0]
26. Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P, Throuvalas N. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002; 20: 3644-3650 [PMID: 12202665]
27. Bafaloukos D, Tsoutsos D, Fountzilas G, Linardou H, Christodoulou C, Kalofonos HP, Briassoulis E, Panagiotou P, Hatzichristou H, Gogas H. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Res 2004; 14: 289-294 [PMID: 15305160]
28. Cortot AB, Gerinière L, Robinet G, Breton JL, Corre R, Falchero L, Berard H, Gimenez C, Chavaillon JM, Perol M, Bombaron P, Mercier C, Souquet PJ. Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Ann Oncol 2006; 17: 1412-1417 [PMID: 16790516 DOI: 10.1093/annonc/mdl146]
29. Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, Lawson D, Dutcher JP, Weiss G, Curti B, Margolin KA. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 2008; 113: 2139-2145 [PMID: 18792064 DOI: 10.1002/cncr.23805]
30. Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ, Krown SE, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 2005; 103: 2590-2597 [PMID: 15861414 DOI: 10.1002/cncr.21081]
31. Iwamoto FM, Omuro AM, Raizer JJ, Nolan CP, Hormigo A, Lassman AB, Gavrilovic IT, Abrey LE. A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2008; 87: 85-90 [PMID: 17987262 DOI: 10.1007/s11060-007-9491-3]
32. Larkin JM, Hughes SA, Beirne DA, Patel PM, Gibbens IM, Bate SC, Thomas K, Eisen TG, Gore ME. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer 2007; 96: 44-48 [PMID: 17146474 DOI: 10.1038/sj.bjc.6603503]
33. Caraglia M, Addeo R, Costanzo R, Montella L, Faiola V, Marra M, Abbruzzese A, Palmieri G, Budillon A, Grillone F, Venuta S, Tagliaferri P, Del Prete S. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother Pharmacol 2006; 57: 34-39 [PMID: 16010592 DOI: 10.1007/s00280-005-0001-z]
34. Bael TE, Peterson BL, Gollob JA. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. Melanoma Res 2008; 18: 147-151 [PMID: 18337652 DOI: 10.1097/CMR.0b013e3282f2a7ae]
35. Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, Karabelis A, Bacoyiannis C, Skarlos DV. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001; 12: 249-254 [PMID: 11300333 DOI: 10.1023/A:1008354323167]
36. Minotti V, Crinò L, Meacci ML, Corgna E, Darwish S, Palladino MA, Betti M, Tonato M. Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer 1998; 20: 93-98 [PMID: 9711527 DOI: 10.1016/S0169-5002(98)00021-X]
37. Chang JE, Khuntia D, Robins HI, Mehta MP. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol 2007; 5: 894-902, 907-915 [PMID: 18185489]
38. van Nifterik KA, van den Berg J, Stalpers LJ, Lafleur MV, Leenstra S, Slotman BJ, Hulsebos TJ, Sminia P. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys 2007; 69: 1246-1253 [PMID: 17967314 DOI: 10.1016/j.ijrobp.2007.07.2366]
39. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999; 43: 795-803 [PMID: 10098435 DOI: 10.1016/S0360-3016(98)00442-8]
40. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745-751 [PMID: 9128946 DOI: 10.1016/S0360-3016(96)00619-0]
41. Koukourakis MI, Romanidis K, Froudarakis M, Kyrgias G, Koukourakis GV, Retalis G, Bahlitzanakis N. Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer 2002; 87: 385-392 [PMID: 12177774 DOI: 10.1038/sj.bjc.6600486]
42. Danson SJ, Middleton MR. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther 2001; 1: 13-19 [PMID: 12113120 DOI: 10.1586/14737140.1.1.13]